Estrogen receptor expression improver, agent for improving physical and mental disorders, and method for screening components that improve physical and mental disorders
A plant extract-based composition from Asparagaceae, especially Asparagus racemosus, addresses reduced estrogen receptor expression due to temperature, improving both physical and mental disorders by enhancing receptor levels.
Patent Information
- Application Number
- JP2023075679
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-01
- Publication Date
- 2024-11-14
AI Technical Summary
The expression level of estrogen receptors is reduced by both ultraviolet rays and temperature, leading to various disorders, and existing compositions primarily address only ultraviolet-induced reductions.
A composition containing plant extracts from the family Asparagaceae, particularly Asparagus racemosus, is used to improve estrogen receptor expression and alleviate disorders caused by hypothermia by increasing receptor levels.
The composition effectively enhances estrogen receptor expression, particularly in hypothermic individuals, thereby mitigating physical and mental disorders associated with low temperatures.
Smart Images

Figure 2024160554000002 
Figure 2024160554000003 
Figure 2024160554000004
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent used for enhancing expression of an estrogen receptor, and also to an agent used for improving mental and physical disorders, and a method for screening a component that improves mental and physical disorders. [Background technology]
[0002] Estrogen is a steroid hormone consisting of three types: estrone, estradiol, and estriol, and is also called the female hormone. All three of the above estrogens have the ability to bind to estrogen receptors, which are present not only in the reproductive organs and mammary glands but also in cells throughout the body.
[0003] Incidentally, it is known that the expression level of estrogen receptors is decreased by ultraviolet rays. Even if the amount of estrogen secreted is normal, if the expression level of estrogen receptors is reduced by ultraviolet rays, the estrogen response will be blunted, causing various disorders. Therefore, various compositions have been developed to enhance the expression of estrogen receptors that has been reduced by ultraviolet light. For example, Patent Document 1 describes a composition for promoting estrogen receptor production in skin cells, which contains an extract of rose petals and pistils containing the placenta as active ingredients. It also describes that the composition for promoting estrogen receptor production increases the expression level of estrogen receptors that has decreased due to ultraviolet rays. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] JP 2018-76271 A Summary of the Invention [Problem to be solved by the invention]
[0005] Under the above circumstances, the present inventors conducted extensive research and discovered that the expression level of estrogen receptors is reduced not only by the effects of ultraviolet light but also by the effects of temperature. Specifically, they discovered that the expression level of the estrogen receptor in culture under relatively low temperature conditions is lower than the expression level of the estrogen receptor in culture under relatively high temperature conditions.
[0006] The present invention was made based on the above novel findings. That is, a first object of the present invention is to provide a novel composition for enhancing the expression of an estrogen receptor, preferably a composition for enhancing the expression of an estrogen receptor under low temperature conditions.
[0007] A second object of the present invention is to provide a novel composition for improving mental and physical disorders caused by hypothermia, based on the above-mentioned new discovery. A third objective of the present invention is to provide a novel method for screening active ingredients of one or more agents selected from agents for enhancing expression of estrogen receptors, agents for improving mental and physical disorders caused by hypothermia, and agents for improving mental and physical disorders in women, based on the above-mentioned new discoveries. [Means for solving the problem]
[0008] The present invention, which solves the first problem, provides an agent used for improving the expression of estrogen receptors, comprising a plant extract belonging to the genus Asparagus in the family Asparagaceae. According to the present invention, the expression level of the estrogen receptor in a subject can be increased.
[0009] The present invention, which solves the second problem, is an agent used for improving mental and physical disorders caused by hypothermia, comprising a plant extract belonging to the genus Asparagus in the family Asparagaceae. The present invention, which solves the second problem, provides an agent for ingestion by a person suffering from hypothermia, which contains a plant extract belonging to the genus Asparagus in the family Asparagaceae. Hypothermia is known to cause various physical and mental disorders, some of which overlap with disorders caused by estrogen dysfunction, which can occur not only due to a decrease in the expression of estrogen itself, but also due to a decrease in the expression of estrogen receptors. As described above, since the expression level of estrogen receptors is reduced under low temperature conditions, it can be said that the expression level of estrogen receptors is also reduced in the body of a hypothermic person. Therefore, according to the present invention, by increasing the expression level of estrogen receptors in a hypothermic person, it is possible to suppress the disturbance of estrogen function and improve physical and mental disorders caused by hypothermia. Therefore, according to the present invention, it is possible to improve mental and physical disorders caused by hypothermia and the disorders felt by people with hypothermia.
[0010] In a preferred embodiment of the present invention, the agent is ingested by a woman. In another preferred embodiment of the present invention, the agent is taken continuously for 10 weeks or more.
[0011] In a preferred embodiment of the present invention, the plant belonging to the genus Asparagus in the family Asparagaceae is Asparagus racemosus.
[0012] The present invention, which solves the third problem mentioned above, is a method for screening active ingredients of one or more agents selected from agents that enhance estrogen receptor expression, agents that improve mental and physical disorders caused by hypothermia, and agents that improve mental and physical disorders in women, using the effect of enhancing estrogen receptor expression at low temperatures as an indicator. According to the present invention, it is possible to screen for components that improve mental and physical disorders caused by hypothermia. Effect of the Invention
[0013] According to the present invention, a novel composition for increasing the expression level of estrogen receptor, preferably the expression level of estrogen receptor in a hypothermic subject, can be provided. Furthermore, according to the present invention, a novel composition that improves mental and physical disorders caused by hypothermia can be provided. Furthermore, according to the present invention, a novel method can be provided for screening active ingredients of one or more agents selected from agents that enhance the expression of estrogen receptors, agents that improve mental and physical disorders caused by hypothermia, and agents that improve mental and physical disorders in women. [Brief description of the drawings]
[0014] [Figure 1] FIG. 2 is a graph showing the expression levels of estrogen receptors in a reference group, a comparative group, and a test group in Test Example 1. [Diagram 2] FIG. 13 is a graph showing changes in responses to questionnaire item (1) in test example 2. [Diagram 3] FIG. 13 is a graph showing changes in responses to questionnaire item (2) in test example 2. [Figure 4] FIG. 13 is a graph showing changes in responses to questionnaire item (3) in Test Example 2. [Diagram 5] FIG. 13 is a graph showing changes in responses to questionnaire item (4) in test example 2. [Figure 6] FIG. 13 is a graph showing changes in responses to questionnaire item (5) in Test Example 2. [Figure 7] FIG. 13 is a graph showing changes in responses to questionnaire item (6) in Test Example 2. [Figure 8] FIG. 13 is a graph showing changes in responses to questionnaire item (7) in Test Example 2. [Figure 9] FIG. 13 is a graph showing changes in responses to questionnaire item (8) in Test Example 2. [Figure 10] FIG. 13 is a graph showing changes in responses to questionnaire item (9) in Test Example 2. [Figure 11]FIG. 13 is a graph showing changes in responses to questionnaire item (10) in test example 2. [Figure 12] FIG. 13 is a graph showing changes in responses to questionnaire item (11) in test example 2. [Figure 13] FIG. 13 is a graph showing changes in responses to questionnaire item (12) in test example 2. [Figure 14] FIG. 13 is a graph showing changes in responses to questionnaire item (13) in test example 2. [Figure 15] FIG. 13 is a graph showing changes in responses to questionnaire item (14) in test example 2. [Figure 16] FIG. 13 is a graph showing changes in responses to questionnaire item (15) in test example 2. [Figure 17] FIG. 13 is a graph showing changes in responses to questionnaire item (16) in test example 2. [Figure 18] FIG. 13 is a graph showing changes in responses to questionnaire item (17) in Test Example 2. [Figure 19] FIG. 13 is a graph showing changes in responses to questionnaire item (18) in test example 2. [Figure 20] FIG. 13 is a graph showing changes in responses to questionnaire item (19) in test example 2. [Figure 21] FIG. 13 is a diagram showing changes in responses to questionnaire item (20) in test example 2. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] The present invention relates to an agent used for enhancing the expression of an estrogen receptor. The agent according to the present invention for use in enhancing the expression of estrogen receptors contains a plant extract belonging to the genus Asparagus in the family Asparagaceae. According to the present invention, the expression of estrogen receptors can be increased.
[0016] In the present invention, the term "low temperature" refers to a relatively low temperature when 37.0°C is used as the standard, and is preferably a temperature of 35.0°C or higher and lower than 36.0°C, and more preferably a temperature of 35.0°C or higher and 35.5°C or lower. In the present invention, the term "hypothermia" includes both hypothermia in an absolute sense and hypothermia in a relative sense. Hypothermia in an absolute sense refers to a condition in which the body temperature is less than 36.0°C when measured in the axilla, preferably a condition in which the body temperature is 35.0°C or higher but less than 36.0°C when measured in the axilla, and more preferably a condition in which the body temperature is 35.0°C or higher but less than 35.5°C when measured in the axilla. Relative hypothermia refers to a relatively low body temperature when there are periods of relatively high body temperature and periods of relatively low body temperature over a certain period of time (e.g., 30 days or one menstrual cycle for women). Also, "hypothermia sufferer" refers to a person who is in a hypothermic state.
[0017] In the present invention, the expression "estrogen receptor expression is improved" means that "the expression level of the estrogen receptor, which has decreased under low temperature conditions, is restored to approximately the expression level of the estrogen receptor at 37° C.," or that "the expression level of the estrogen receptor in a hypothermic subject is improved to approximately the expression level of the estrogen receptor in a non-hypothermic subject." In other words, in the present invention, it is not required that the expression level of the estrogen receptor under low temperature conditions exceeds the expression level of the estrogen receptor at 37° C., or that the expression level of the estrogen receptor in a hypothermic subject exceeds the expression level of the estrogen receptor in a non-hypothermic subject.
[0018] In the present invention, plants belonging to the genus Asparagus in the family Asparagaceae are not particularly limited, and examples thereof include, but are not limited to, Asparagus schoberioides, Asparagus cochinensis, Asparagus kiusianus, Asparagus oligoclonis, Asparagus officinalis L., and Asparagus racemosus. Preferably, the plant belonging to the genus Asparagus of the family Asparagaceae is Asparagus racemosus. Hereinafter, in this specification, the scientific name of each plant may be abbreviated.
[0019] In the present invention, examples of plant extracts belonging to the genus Asparagaceae include extracts made from wild or cultivated plants, extracts made from plants sold as raw materials for herbal medicines, and commercially available extracts. When extracting the above-mentioned extract, the part of the plant body to be extracted is not particularly limited, but it is preferable to extract from the root. In addition, the plant body of the plant belonging to the Asparagaceae family and the genus Asparagus may be used as it is for the extraction operation, but it is preferable to crush or cut the plant body in advance to improve the extraction efficiency.
[0020] Suitable examples of the extraction solvent include one or more selected from the following polar solvents: water, alcohols such as ethanol, methanol, 1,3-butanediol, and propylene glycol, esters such as ethyl acetate and methyl formate, ketones such as acetone and methyl ethyl ketone, halogenated hydrocarbons such as chloroform and methylene chloride, nitriles such as acetonitrile, and ethers such as diethyl ether and tetrahydrofuran. More preferred extraction solvents are water and / or alcohols, and even more preferred extraction solvents are ethanol. A specific method for extracting the above-mentioned extract includes, for example, adding 1 to 10 parts by mass of a solvent to 1 mass of a plant belonging to the genus Asparagaceae or its dried matter, soaking the plant for several days at room temperature or for several hours at a temperature near the boiling point, cooling to room temperature, and then removing insoluble matter as desired, but the extraction method is not limited thereto. Also, the extract obtained by the above-mentioned method can be dried by adding an excipient as desired to obtain a powder. As the extraction solvent, it is preferable to use a mixed solvent of ethanol and water.
[0021] The agent of the present invention used for enhancing the expression of the estrogen receptor can be in the form of an oral composition or an external preparation for the skin. Preferably, the estrogen expression enhancer of the present invention is an oral composition.
[0022] When the agent for improving the expression of the estrogen receptor of the present invention is an oral composition, suitable examples include food and drink (preferably health food), supplements (nutritional supplements), quasi-drugs, medicines, etc., but since it can be used daily, it is more preferable that the food and drink contains a plant belonging to the Asparagaceae family, Asparagus genus, as an active ingredient. Specifically, it can be in the form of general food, health food, tablets, granules, drinks, capsules, powders, etc., and these can be manufactured by conventional methods.
[0023] When the agent used to improve the expression of estrogen receptors is an oral composition, the content of the plant extract belonging to the genus Asparagaceae of the family Asparagaceae in the agent is 0.01% by mass or more, more preferably 0.05% by mass or more, and more preferably 0.1% by mass or more (dry mass) in terms of solid content. By setting the lower limit of the content of the plant extract belonging to the genus Asparagaceae in the family Asparagaceae within the above-mentioned numerical range, it is possible to improve the expression of estrogen receptors in the body. In addition, the upper limit of the content of the plant extract belonging to the genus Asparagaceae of the Asparagaceae family in an agent used to improve the expression of estrogen receptors can be set as appropriate, and can be, for example, 90% by mass or less in terms of solid content, preferably 70% by mass or less, and more preferably 50% by mass or less (dry mass).
[0024] When the agent used for improving the expression of the estrogen receptor of the present invention is an oral composition, it may contain ingredients other than the plant extract belonging to the genus Asparagaceae, Asparagaceae, within a range that does not impair the effect of improving the expression of the estrogen receptor, depending on the dosage form, desired flavor, etc. For example, when the agent used to improve the expression of the estrogen receptor of the present invention is a food or drink (health food), suitable examples of the agent include seasoning ingredients such as salt, sugar, monosodium glutamate, monosodium inosinate, vinegar, etc., coloring ingredients, odor correcting ingredients such as flavors, thickeners, emulsifiers / dispersants, preservatives, stabilizers, various vitamins, etc. Furthermore, if the agent used to improve the expression of the estrogen receptor of the present invention is a supplement, a quasi-drug, or a pharmaceutical, suitable examples of the agent include excipients such as crystalline cellulose and lactose, binders such as gum arabic and hydroxypropyl cellulose, disintegrants such as croscarmellose sodium and starch, lubricants such as magnesium stearate, flavorings, colorants, various vitamins, pH adjusters, etc.
[0025] When the agent used for improving the expression of the estrogen receptor of the present invention is an external preparation for the skin, the content of the plant extract belonging to the genus Asparagaceae of the family Asparagaceae is preferably 0.000001 to 0.005% by mass, and more preferably 0.00001 to 0.0005% by mass (dry mass) of the entire composition.
[0026] When the agent used for improving the expression of the estrogen receptor of the present invention is an external preparation for the skin, it may contain optional ingredients such as whitening ingredients, wrinkle-improving ingredients, anti-inflammatory ingredients, and extracts derived from animals and plants, within a range that does not impair the effect of improving the expression of the estrogen receptor. These optional ingredients may be commercially available and used, or may be synthesized by a known method and used. Each optional ingredient may have two or more effects (for example, a whitening effect and an anti-wrinkle effect). The optional components may be appropriately selected depending on the dosage form.
[0027] Examples of whitening ingredients include 4-n-butylresorcinol, ascorbic acid glucoside, 3-O-ethyl ascorbic acid, tranexamic acid, arbutin, 1-triphenylmethylpiperidine, 1-triphenylmethylpyrrolidine, 2-(triphenylmethyloxy)ethanol, 2-(triphenylmethylamino)ethanol, 2-(triphenylmethyloxy)ethylamine, triphenylmethylamine, triphenylmethanol, triphenylmethane and aminodiphenylmethane, N-(o-toluoyl)cysteic acid, N-(m-toluoyl)cysteic acid, N-(p-toluyl)cysteic acid, N-(p-methoxybenzoyl)cysteic acid, N-benzoyl-serine, N-(p-methyl)-2-phenylpropanediol ... N-(p-ethylbenzoyl)serine, N-(p-methoxybenzoyl)serine, N-(p-fluorobenzoyl)serine, N-(p-trifluoromethylbenzoyl)serine, N-(2-naphthoyl)serine, N-(4-phenylbenzoyl)serine, N-(p-methylbenzoyl)serine methyl ester, N-(p-methylbenzoyl)serine ethyl ester, N-(2-naphthoyl)serine methyl ester, N-benzoyl-O-methylserine, N-(p-methylbenzoyl)-O-methylserine, N-(p-methylbenzoyl)-O-acetylserine, N-(2-naphthoyl)-O-methylserine, dexpanthenol W, niacinamide, and the like.
[0028] The content of the whitening ingredient is usually 0.0001 to 30% by mass, preferably 0.001 to 10% by mass, and more preferably 0.01 to 5% by mass (dry mass in the case of an extract).
[0029] Examples of wrinkle-improving ingredients include vitamin A or its derivatives such as retinol, retinal, retinoic acid, tretinoin, isotretinoin, tocopherol retinoate, retinol palmitate, and retinol acetate.Further examples include ursolic acid benzyl ester, ursolic acid phosphate, betulinic acid benzyl ester, benzilic acid phosphate, trifluoroisopropyloxopropylaminocarbonylpyrrolidinecarbonylmethylpropylaminocarbonylbenzoylaminosodium acetate, and niacinamide.
[0030] The content of the wrinkle-improving ingredient is usually 0.0001 to 30% by mass, preferably 0.001 to 10% by mass, and more preferably 0.01 to 5% by mass (dry mass in the case of an extract).
[0031] Examples of anti-inflammatory components include clarinone, glabridin, glycyrrhizinic acid, glycyrrhetinic acid, pantothenyl alcohol, niacinamide, tranexamic acid, and the like, and preferred examples include glycyrrhizinic acid and its salts, alkyl glycyrrhetinates and their salts, and glycyrrhetinic acid and its salts. The content of the anti-inflammatory component is usually 0.01 to 30% by mass, preferably 0.1 to 10% by mass, and more preferably 1 to 5% by mass (dry mass in the case of an extract).
[0032] Examples of extracts derived from plants and animals include akebia extract, asarum extract, avocado extract, amacha extract, almond extract, arnica extract, aronia extract, apricot extract, ginkgo extract, fennel extract, udo extract, eleuthero extract, emmeiso extract, phellodendron bark extract, ginseng extract, white lamb extract, kakyoku extract, pueraria root extract, chamomile extract, carrot extract, artemisia capillaris extract, licorice extract, kiwi extract, cucumber extract, guava extract, and gardenia extract. , Kumazasa extract, Walnut extract, Black rice extract, Chlorella extract, Mulberry extract, Kankegumo extract, Alpinia speciosa extract, Gentian extract, Rice extract, Fermented rice extract, Fermented rice bran extract, Rice germ oil, Salvia extract, Soapwort extract, Sasa extract, Sandalwood extract, Zanthoxylum extract, Shiitake mushroom extract, Rehmannia root extract, Lithospermum root extract, Perilla extract, Tilia extract, Spiraea extract, Ginger extract, Calamus root extract, Horsetail extract, Stevia extract, Fermented stevia, Achillea millefolium Kiss, peppermint extract, sage extract, mallow extract, cnidium extract, swertia bristlecone extract, soybean extract, tsinga extract, dandelion extract, clove extract, chili pepper extract, angelica extract, calendula extract, peach kernel extract, houttuynia extract, tomato extract, natto extract, carrot extract, garlic extract, hibiscus extract, burdock extract, lotus extract, parsley extract, birch extract, witch hazel extract, sedge extract, cypress extract, loquat Preferred examples of extracts include coltsfoot extract, butterbur extract, poria extract, loofah extract, peppermint extract, linden extract, pine extract, skunk cabbage extract, melissa extract, mozuku extract, peach extract, cornflower extract, lily extract, coix seed extract, mugwort extract, lavender extract, apple extract, rooibos tea extract, lychee extract, lettuce extract, forsythia extract, astragalus extract, rosemary extract, Roman chamomile extract, and burnet extract.
[0033] The content (dry mass) of the animal and plant-derived extract is usually 0.01 to 30 mass %, preferably 0.1 to 10 mass %, and more preferably 0.3 to 3 mass %.
[0034] When the agent used to improve the expression of the estrogen receptor of the present invention is an external preparation for the skin, other ingredients that can be added besides those mentioned above include polyols such as polyethylene glycol, glycerin, 1,3-butylene glycol, erythritol, sorbitol, xylitol, maltitol, propylene glycol, dipropylene glycol, diglycerin, isoprene glycol, 1,2-pentanediol, 2,4-hexylene glycol, 1,2-hexanediol, and 1,2-octanediol, fatty acid soaps (sodium laurate, sodium palmitate), and the like. etc.), anionic surfactants such as potassium lauryl sulfate and alkyl sulfate triethanolamine ether, cationic surfactants such as stearyl trimethylammonium chloride, benzalkonium chloride and laurylamine oxide, imidazoline-based amphoteric surfactants (2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt etc.), betaine-based surfactants (alkyl betaine, amido betaine, sulfo betaine etc.), amphoteric surfactants such as acyl methyl taurine, sorbitan fatty acid esters (sorbitan monostearate) , sorbitan sesquioleate, etc.), glycerin fatty acids (glycerin monostearate, etc.), propylene glycol fatty acid esters (propylene glycol monostearate, etc.), hydrogenated castor oil derivatives, glycerin alkyl ether, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbitan fatty acid esters (POE-sorbitan monolaurate, etc.), POE glycerin fatty acid esters (POE-glycerin monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ethers (POE 2-octyldodecyl ether, etc.), POE alkyl phenyl ethers (POE nonylphenyl ether, etc.), Pluronic (registered trademark) types, POE·POP alkyl ethers (POE·POP 2-decyltetradecyl ether, etc.), Tetronics, POE castor oil / hydrogenated castor oil derivatives (POE castor oil, POE hydrogenated castor oil, etc.), sucrose fatty acid esters, nonionic surfactants such as alkyl glucosides, sodium pyrrolidone carboxylate,Moisturizing ingredients such as lactic acid and sodium lactate; powders such as mica, talc, kaolin, synthetic mica, calcium carbonate, magnesium carbonate, anhydrous silicic acid (silica), aluminum oxide, and barium sulfate, which may be surface-treated; inorganic pigments such as cobalt oxide, ultramarine, Prussian blue, and zinc oxide, which may be surface-treated; composite pigments such as sintered iron oxide and titanium dioxide, which may be surface-treated; pearling agents such as titanium mica, fish phosphorus foil, and bismuth oxychloride, which may be surface-treated; Red No. 202, Red No. 228, Red No. 226, Yellow No. 4, Blue No. 404, Yellow No. 5, Red No. 505, Red No. 230, Red No. 223, Orange No. 201, Red No. 213, Yellow No. 204, and Yellow No. 203, which may be laked. Examples of suitable organic pigments include Blue No. 1, Green No. 201, Purple No. 201, and Red No. 204; organic powders such as polyethylene powder, polymethylmethacrylate, nylon powder, and organopolysiloxane elastomer; lower alcohols such as ethanol and isopropanol; vitamin A or a derivative thereof; vitamin B such as vitamin B6 hydrochloride, vitamin B6 tripalmitate, vitamin B6 dioctanoate, vitamin B2 or a derivative thereof, vitamin B12, and vitamin B15 or a derivative thereof; vitamin E such as α-tocopherol, β-tocopherol, γ-tocopherol, and vitamin E acetate; vitamin D, vitamin H, pantothenic acid, pantethine, and pyrroloquinoline quinone.
[0035] As described above, the present inventors discovered that the expression level of estrogen receptor decreases at low temperatures. From these results, it is presumed that the expression level of estrogen receptors is decreased in people with hypothermia. Therefore, the agent for improving the expression of estrogen receptors according to the present invention is preferably one for ingestion by a person with low body temperature, which can improve the expression level of estrogen receptors in the person with low body temperature.
[0036] The present invention also relates to an agent for improving mental and physical disorders caused by hypothermia. As mentioned above, the expression level of estrogen receptors decreases at low temperatures, so people with hypothermia have low expression levels of estrogen receptors due to their low body temperature, which disrupts the function of estrogen and can cause various physical and mental ailments. The present inventors have demonstrated that plant extracts belonging to the genus Asparagus in the family Asparagaceae (particularly Asparagus racemosus extract) improve the expression of estrogen receptors at low temperatures. Therefore, by improving the expression of estrogen receptors in people with hypothermia, it is expected that the disruption of estrogen function will be suppressed and physical and mental disorders caused by hypothermia will be improved.
[0037] As a preferred embodiment of the agent used for improving mental and physical disorders caused by hypothermia, the items described above regarding the agent used for enhancing the expression of the estrogen receptor can be applied as is.
[0038] In the present invention, the "mental and physical disorders caused by hypothermia" are not particularly limited as long as they are physical and / or mental disorders felt due to a decrease in the expression level of estrogen receptors caused by hypothermia. The mental and physical disorders caused by hypothermia only need to be subjectively felt as disorders by the person taking the agent used for improving mental and physical disorders according to the present invention, and do not need to be judged as specific diseases. In addition, the mental and physical disorders caused by hypothermia may be disorders that can be caused by hypothermia as one cause, and may be disorders that can be caused by disturbances in the action of estrogen caused by a decrease in the expression level of estrogen receptors, or may be disorders that can be caused by other causes. Furthermore, it is not necessary for the person taking the agent for improving mental and physical disorders according to the present invention to be aware that the mental and physical disorders are caused by hypothermia.
[0039] Physical discomfort resulting from hypothermia may include, but is not limited to, difficulty falling asleep / light sleep, fatigue, feeling heavy / lazy, face hot, sweating easily, stomach problems (constipation / stomach pain / diarrhea), skin inflammation or redness / increased skin tone, acne or pimples appearing / easier to appear, dull skin / worsening dullness, loss of skin luster, and makeup not sticking well. In addition, examples of mental disorders resulting from hypothermia include, but are not limited to, the severity of overall illness, irritability (tending to be irritable), feeling depressed (tending to be anxious), feeling like not being yourself, smiling less, being in a bad mood, not being able to enjoy fashion, trying to avoid social interactions, etc.
[0040] The present invention also relates to an agent for use by being ingested by a person suffering from hypothermia, which contains an extract of a plant belonging to the genus Asparagaceae and the family Asparagaceae. As described above, based on the findings of the present inventors, it is highly likely that hypothermic individuals have a reduced expression level of estrogen receptors due to their hypothermia. Therefore, by using it as an agent for people with hypothermia, it is possible to increase the expression level of estrogen receptors in the bodies of people with hypothermia, which is expected to improve the discomfort felt by people with hypothermia. As for the preferred form of the agent to be ingested by a person with hypothermia, the matters described above regarding the agent used to increase the expression of the estrogen receptor and the agent used to improve mental and physical disorders caused by hypothermia can be applied as is.
[0041] The dosage of the agent used to improve the expression of the estrogen receptor according to the present invention, the agent used to improve mental and physical disorders caused by hypothermia, and the agent to be ingested by individuals with hypothermia can be appropriately set within a range that does not adversely affect the human body. The intake amount of the plant extract belonging to the genus Asparagaceae, Asparagaceae, as a solid content, can be 1 mg or more, 5 mg or more, 10 mg or more, 20 mg or more, or 30 mg or more per day. Furthermore, the intake amount of the plant extract belonging to the genus Asparagaceae, family Asparagaceae, as a solid content, can be 200 mg or less, 150 mg or less, 100 mg or less, 50 mg or less, or 40 mg or less per day.
[0042] Furthermore, when the intake period is at least once a day, the intake period may be 4 consecutive weeks or more, 6 consecutive weeks or more, 8 consecutive weeks or more, 9 consecutive weeks or more, 10 consecutive weeks or more, 11 consecutive weeks or more, or 12 consecutive weeks or more. By setting the intake period to the above period, the effect of the agent according to the present invention can be more effectively exhibited.
[0043] In addition, the sex of the person who takes the agent for improving the expression of the estrogen receptor according to the present invention, the agent for improving mental and physical disorders caused by hypothermia, and the agent for use by being taken by a person with hypothermia is not particularly limited.From the viewpoint of being easily affected by the disturbance of the action of estrogen, the sex of the person who takes the agent for improving the expression of the estrogen receptor according to the present invention, the agent for improving mental and physical disorders caused by hypothermia, and the agent for use by being taken by a person with hypothermia is preferably female.
[0044] The present invention also relates to a screening method for the active ingredients of one or more agents selected from agents that enhance estrogen receptor expression, agents that improve mental and physical disorders caused by hypothermia, and agents that improve mental and physical disorders in women, using the effect of enhancing estrogen receptor expression at low temperatures as an indicator. As described above, the present inventors have clarified that the expression level of estrogen receptors is decreased at low temperatures. Furthermore, in people with low body temperature, the expression level of estrogen receptors is decreased, which may cause people with low body temperature to experience various disorders. According to the present invention, it is possible to screen for active ingredients of one or more agents selected from agents for enhancing expression of estrogen receptors, agents for improving mental and physical disorders caused by hypothermia, and agents for improving mental and physical disorders in women.
[0045] The screening method according to the present invention includes a step of culturing cells in the presence of a test substance. If necessary, pre-cultured cells may be used. The cells to be used are not particularly limited as long as the expression level of the estrogen receptor can be confirmed. For example, human dermal fibroblasts can be used. The medium used for cell culture is not particularly limited, and a medium suitable for the cells used may be appropriately selected. In addition, the culture conditions are not particularly limited as long as the culture is performed at a low temperature, and known conditions can be appropriately selected depending on the cells used.
[0046] The test substance to be screened is not particularly limited, and examples thereof include commercially available compounds, known compounds, extracts derived from animals and plants, etc. Furthermore, the extracts derived from animals and plants may be those that have been fractionated, purified, or solvent removed, etc. Furthermore, the extracts derived from plants include extracts using wild or cultivated plants, extracts sold as raw materials for herbal medicines, etc., commercially available extracts, etc.
[0047] The expression level of the estrogen receptor can be measured by any known method. For example, after sufficient culture, estrogen receptor mRNA can be collected from the cells, and the expression level of estrogen receptor mRNA can be measured by RT-qPCR. Primers used in RT-qPCR can be commercially available as appropriate.
[0048] In a preferred embodiment of the present invention, when the expression level of estrogen receptor in cells cultured under low temperature conditions in the presence of a test substance is increased compared to the expression level of estrogen receptor in cells cultured under low temperature conditions in the absence of a test substance, the test substance is judged to be an active ingredient of one or more agents selected from an agent for enhancing expression of estrogen receptor, an agent for improving mental and physical disorders caused by hypothermia, and an agent for improving mental and physical disorders in women. In this case, the expression level of estrogen receptor in cells cultured under low temperature conditions in the presence of the test substance does not need to exceed the expression level of estrogen receptor in cells cultured at 37°C (regardless of whether the test substance is present or not). According to the present invention, it is possible to screen for components that improve mental and physical disorders caused by hypothermia. EXAMPLES
[0049] The present invention will be described in more detail below with reference to examples, but the technical scope of the present invention is not limited to the following examples.
[0050] <Example 1> In this example, changes in the expression level of estrogen receptor depending on the culture temperature were examined.
[0051] (Test substance) The test substance used was Asparagus racemosus extract powder (manufactured by Sabinsa Japan Corporation). The extract powder is a powder containing 60-70% Asparagus racemosus extract and 30-40% dextrin.
[0052] (Experimental Method) (1) Normal human dermal fibroblasts (collected from the abdomen of a 45-year-old adult female) were cultured in a 6-well plate at 4.0 × 10 4 Cells were seeded at 1000 cells / well and incubated overnight at 37°C (pre-incubation). (2) Precultured normal human dermal fibroblasts were divided into three groups: a group cultured at 37°C (reference group), a group cultured at 35°C without the test substance (comparison group), and a group cultured at 35°C using a medium containing Asparagus racemosus extract powder (test group), and each group was cultured for three days. In the test group, Asparagus racemosus extract powder was added as a raw material at 60 μg / mL, and fresh 10% FBS-containing DMEM medium was used as the medium. (3) After three days of culture, estrogen receptor (ERβ) mRNA was extracted from the normal human dermal fibroblasts cultured in each group using standard methods, and the expression levels of estrogen receptor (ERβ) mRNA were measured using RT-qPCR.
[0053] The expression level of estrogen receptor (ERβ) mRNA in each group was quantified by the following method: The RPL37A gene was used as an internal standard. (1) cDNA synthesis cDNA synthesis was performed using ReverTra Ace (R) qPCR was performed using RT Master Mix (TOYOBO, #FSQ-201, lot 251800). (R) qPCR RT Master Mix was mixed with 8 μL of 0.125 μg / μL total RNA solution (estrogen receptor (ERβ or RPL37A)) and reacted at 37°C for 15 minutes, 50°C for 5 minutes, and 98°C for 5 minutes to obtain each cDNA. (2) Quantitative PCR Quantitative PCR was performed using the cDNA synthesized in (1) above. PCR reactions were performed according to the manual for THUNDERBIRD Next SYBR qPCR / UNG Set (TOYOBO, #QPX201 / UNG101, lot 257400 / 2211022). The sequences of the primers used are shown in Table 1 below.
[0054] [Table 1]
[0055] The ERβ gene expression level of each sample calculated from the standard curve was corrected by dividing it by the expression level of the internal standard gene RPL37A (ERβ / RPL37A), and the relative expression level was calculated with the average value of ERβ / RPL37A in the group cultured at 37°C (reference group) set as 100%. The relative expression levels of ERβ in the comparison group and the test group compared to the reference group are shown in FIG.
[0056] As shown in FIG. 1, the expression level of the estrogen receptor in the comparison group was decreased compared to the expression level of the estrogen receptor in the reference group. On the other hand, the expression level of the estrogen receptor in the test group was higher than that in the comparison group and was close to that of the reference group. These results suggest that Asparagus racemosus extract has the effect of increasing the expression of estrogen receptors, especially under low temperature conditions. In addition, cell culture at 35℃ reproduced the condition of hypothermic subjects. Therefore, the above results suggest that Asparagus racemosus extract has the effect of improving the expression of estrogen receptors, especially in hypothermic subjects.
[0057] <Test Example 2> In this test example, a 12-week continuous use test was conducted on a composition containing Asparagus racemosus extract powder.
[0058] The subjects were 30 women aged 20 to 53 years (mean age 38.57 ± 10.14 years). In this test, the test sample was a tablet containing the same Asparagus racemosus extract powder as the active ingredient as in Test Example 1. The concentration of Asparagus racemosus extract powder in one tablet (300 mg) of the test sample was 16 mg (the extract concentration per tablet was approximately 0.053% by mass as the raw material). The subjects were instructed to take two tablets once a day with water or lukewarm water for 12 weeks (daily intake of Asparagus racemosus extract powder was 32 mg). The subjects were asked to fill out the same questionnaire before the start of the study, after 4 weeks of intake, and after 12 weeks of intake, and changes in the answers were analyzed using statistical processing. Thirty subjects filled out the questionnaire before the start of the study and after 4 weeks of intake, and 28 subjects filled out the questionnaire after 12 weeks of intake.
[0059] The questionnaire items in this test example are as follows. Each subject answered each item subjectively. In the questionnaire, subjects were asked to answer how they felt about each questionnaire item on a 10-point scale, with 1 being "not felt at all" and 10 being "felt strongly." (Survey items) (1) The severity of the overall illness (2) I feel angry (irritated) (3) Feeling depressed (worried) (4) Difficulty falling asleep or shallow sleep (5) Feeling tired easily (6) Feeling heavy (tired) (7) Feeling hot on the face (8) I feel like I sweat easily (9) Stomach problems such as constipation, stomach pain, or diarrhea (10) Skin irritation (inflammation or redness) (11) I have dry skin (acne, pimples) (12) I feel my skin is dull (dark) (13) I feel my skin lacks luster (14) I feel like my makeup doesn’t stick well. (15) I feel that my facial expression is frowning, with a furrowed mouth or wrinkles between the eyebrows. (16) I feel like I can’t be myself (17) I feel like I smile less (18) Feeling in a bad mood (19) I feel unable to enjoy fashion, makeup, or other stylish things. (20) Wanting to avoid social interactions (not wanting to meet people)
[0060] Comparisons of responses before the start of the study and after 4 weeks of intake, comparisons of responses before the start of the study and after 4 weeks of intake, and comparisons of responses before the start of the study and after 12 weeks of intake are shown in Figures 2 to 21.
[0061] As shown in Figures 3, 4, 6, 11, 16, and 19, the following questionnaire items were reduced after 4 weeks of intake: (2) feeling irritable (irritated), (3) feeling depressed (worried), (5) feeling fatigued easily, (10) feeling rough skin (inflammation or redness), (15) feeling like you have a bad mood, such as a furrowed mouth or wrinkles between the eyebrows, and (18) feeling like you are in a bad mood. In other words, for these six items, taking two tablets once a day for four weeks improved physical and mental disorders. In addition, as shown in Figures 2 to 21, the scores for all the above questionnaire items decreased after 12 weeks of ingestion. In other words, mental and physical disorders improved for all items after taking two tablets once a day for 12 weeks. From the above results, it was shown that Asparagus racemosus extract has an effect of improving mental and physical disorders when taken once a day or more for at least 4 weeks.Furthermore, from the above results, it was shown that Asparagus racemosus extract has an effect of improving mental and physical disorders when taken once a day or more for preferably 10 weeks or more, more preferably 11 weeks or more, and even more preferably 12 weeks or more.
[0062] As described above, the discomforts related to the questionnaire items are caused in part by a decrease in the expression level of estrogen receptors due to hypothermia. Therefore, the above results suggest that the agent according to the present invention has the effect of improving mental and physical disorders caused by hypothermia.
[0063] Furthermore, the results of Test Examples 1 and 2 suggest that the effect of improving the expression level of estrogen receptors at low temperatures can be used as an indicator to screen for active ingredients of one or more agents selected from agents that improve the expression level of estrogen receptors, agents that improve mental and physical disorders caused by hypothermia, and agents that improve mental and physical disorders in women. [Industrial Applicability]
[0064] According to the present invention, the expression level of the estrogen receptor can be increased. Furthermore, according to the present invention, it is possible to improve the mental and physical disorders of people with hypothermia (mental and physical disorders caused by hypothermia). Furthermore, according to the present invention, it is possible to screen for active ingredients of one or more agents selected from agents that enhance the expression of estrogen receptors, agents that improve mental and physical disorders caused by hypothermia, and agents that improve mental and physical disorders in women.
Claims
1. An agent used for improving expression of estrogen receptors, comprising a plant extract belonging to the genus Asparagus of the family Asparagaceae.
2. An agent used for improving mental and physical disorders caused by hypothermia, comprising a plant extract belonging to the genus Asparagus of the family Asparagaceae.
3. An agent for ingestion by a person suffering from hypothermia, comprising a plant extract belonging to the genus Asparagus of the family Asparagaceae.
4. The agent according to any one of claims 1 to 3, which is administered to women.
5. The agent according to any one of claims 1 to 3, which is to be taken continuously for 10 weeks or more.
6. The agent for use in enhancing expression of an estrogen receptor according to any one of claims 1 to 3, wherein the plant belonging to the genus Asparagus of the family Asparagaceae is Asparagus racemosus.
7. A screening method for the active ingredients of one or more agents selected from agents for enhancing estrogen receptor expression, agents for improving mental and physical disorders caused by hypothermia, and agents for improving mental and physical disorders in women, using the effect of enhancing estrogen receptor expression at low temperatures as an indicator.
Citation Information
Patent Citations
Estrogen receptor production promoting composition
JP2018076271A
